Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN, OTCQB:KHRNF), Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced the official launch of the Company’s Kuida brand in the United States. Beginning this Wednesday, November 20, Kuida’s line of CBD skincare products will become available for purchase to US consumers at retail, initially in Los Angeles, before a planned expansion in priority US states where sale of hemp-derived CBD is permitted.


Kuida’s line of CBD skincare products will become available for purchase to US consumers at Cannabis Now’s store in Los Angeles, CA. Khiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.)


Kuida’s line of CBD skincare products will become available for purchase to US consumers at Cannabis Now’s store in Los Angeles, CA. (CNW Group/Khiron Life Sciences Corp.)


Kuida’s line of CBD skincare products will become available for purchase to US consumers at Cannabis Now’s store in Los Angeles, CA. (CNW Group/Khiron Life Sciences Corp.)

In the California market, Kuida will initially be distributed and sold through a partnership with leading lifestyle media and retail brand, Cannabis Now. With a prime flagship location in Los Angeles and an expanding retail network including three planned stores across major US cities, Cannabis Now offers a selection of non-THC health and wellness products in an experiential retail environment designed to educate both experienced and new cannabis consumers. Through an exclusive activation at Cannabis Now’s high-traffic Beverly Hills location, the Kuida brand will target an affluent, on-trend audience of beauty and cannabis consumers, influencers, and professionals across Los Angeles as well as the wider US market.

“We are incredibly proud to be the first Colombian brand to introduce legal CBD products in the US market,” stated Elsa Navarro, Skin Unit Director of Khiron Life Sciences. “As we enter the United States market and commence sales, we bring proven success in brand building, a scientifically-backed, GMP lab made product, and a powerful branding and marketing campaign that resonates with consumers. As a result, we find ourselves in a strong position to reach consumers and gain market share in the fast-growing US skincare market.”

Eugenio Garcia, CEO and Founder at Cannabis Now comments: “At Cannabis Now, we are disrupting the cannabis retail space to introduce first-of-its-kind experiential and education-focused experiences. Khiron shares our commitment to innovation and high-quality products that help improve the consumer experience, and Kuida is an ideal addition to our retail marketplace. We are very excited to share Kuida with our customer base and wide following in the US.”

In addition to in-store programming, the Company will also support the retail pop-up and drive sales through a comprehensive marketing campaign spanning mass media, experiential activations, social media, and influencer partnerships. Kuida will further collaborate with Cannabis Now on educational content as well as print and digital advertising, leveraging the brand’s media offering to reach its following of 4.2 million US consumers.

The introduction of Kuida in the United States will kick off with a launch event on Wednesday, November 20th at Cannabis Now with the Khiron executive team, beauty experts and lifestyle influencers. Investors are invited to experience Kuida for themselves and to join Khiron Life Sciences as they celebrate this momentous milestone!

Kuida Kick-Off Event Details
Wednesday, November 20th
7:00 PM
Cannabis Now
8495 W. 3rd Street
Los Angeles

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN, OTC:KHRNF) for an Investor Presentation.


American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less